SBC Medical Group Holdings (SBC) Q3 2026 earnings review
SBC Medical raises clinic fees, but patient spending growth slows
SBC Medical Group, which provides management and supplies to partner medical clinics, grew revenue fast by charging those clinics higher fees even as patient spending slowed. Third-quarter revenue rose 35% from a year ago to $59 million — or about 24% excluding the acquired Waqoo business by our math — and operating margin jumped 9 percentage points to 45%. Chairman and chief executive Yoshiyuki Aikawa said growth and profit are improving together after August's fee hikes.
| Revenue excluding Waqoo (by our math) | +24% headline revenue: $58.6M (+35% from a year ago) |
|---|---|
| Operating margin | 45% +8.5 percentage points from a year ago |
| Patient visits (past 12 months) | 7.06M +9% from a year ago (10% last quarter) |
| Annualized fee uplift plan | In effect August fee revisions began in Q3; no numeric full-year outlook |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because 91% of revenue still comes from clinics controlled by the chief executive's family, and the revenue jump reflects a contract fee hike rather than faster demand at the clinics. While the August fee increase lifted operating profit and pushed net cash to $154 million, patient visit growth edged down to 9% and average spend per visit growth slowed to 4%.
The question now is whether the partner clinics are earning enough from patients to keep paying the higher management fees without cutting them back later. Either the fee hike captures real clinic productivity gains, or it shifts profit from the family's clinics to the public company while clinic growth cools. The third-quarter filing's breakdown of standalone management fee revenue and clinic category mix will show how much underlying demand contributed.
🐂 Bull Case
Higher Clinic Fees Lifted the Operating Margin
SBC Medical is a medical services organization (MSO), meaning it provides management, marketing and equipment to partner clinics for a fee. In August, the company raised its call-center and support fees for partner clinics by an estimated $15 million a year, pairing the increase with new AI tools. Those higher fees took effect this quarter and pushed revenue up 35.1% from a year ago to $58.6 million.
Because the company delivers these management services with its existing staff, the extra fee revenue carried almost no new cost. Operating margin jumped 8.5 percentage points from a year ago to 45.1%. Selling, general and administrative expenses — overhead and marketing costs — fell by 7.1 percentage points of revenue to 26.9%, while the cost of revenues — direct supply and service costs — fell 1.4 percentage points to 28.0%.
What to watch: the management services revenue line in the third-quarter filing. A figure of $14.5 million or higher would confirm that the August fee hike is flowing through at its full quarterly run-rate.
Operating Cash Flow Lifted Net Cash to $154M
The company generated $50.2 million in cash from operations over the first nine months of 2026, reversing a $27.3 million cash outflow in the same period last year. By our math, subtracting first-half results leaves $18.5 million of operating cash flow and $17.4 million of free cash flow in the third quarter alone. Cash and equivalents reached $198.4 million at the end of September.
Subtracting $33.6 million in bank debt and finance leases and $10.3 million in operating leases leaves $154 million in net cash. The company also paid down $8.9 million of bank debt during the first nine months and spent nothing on share buybacks, leaving its $20 million repurchase plan untouched before it expires in December.
What to watch: whether the board extends the $20 million buyback plan at year-end or spends the cash pile on clinic acquisitions.
🐻 Bear Case
Related-Party Fees Drive Growth While Clinic Demand Slows
"The third quarter of 2026 marked a strong reacceleration in SBC Medical’s growth," chairman and chief executive Yoshiyuki Aikawa said. The company attributed the 35.1% revenue rise to "the impact of service fee structure revisions announced in August, as well as the consolidation of Waqoo", a Japanese skin-care and research group acquired late last year. By our math, stripping out Waqoo's roughly $5 million quarterly run-rate leaves underlying revenue up about 24%.
- Related-party revenue: $53.5 million, or 91.4% of total revenue, up $9.8 million from last quarter by our math
- Patient visits over the past 12 months: 7.06 million, up 9% from a year ago, slowing from 10% in the second quarter
- Average spend per visit: $290, up 4% from a year ago, slowing from 11% in the first quarter
Almost all of the revenue jump came from related parties — medical corporations controlled by Aikawa's relatives. Meanwhile, patient traffic and spending growth at the clinics themselves both slowed down. Because the chief executive's family sits on both sides of the fee contracts, SBC Medical can raise its own revenue by charging the clinics more even when patient demand cools.
What to watch: SBC Core segment revenue in the quarterly filing. A figure below $46 million would mean the core business fell short of the full $3.75 million quarterly fee uplift.
Acquisitions Supply Over a Third of Yearly Clinic Additions
SBC Medical aims to support 1,000 clinics by 2035 and relies on acquisitions to get there, which brings deal costs and losses from minority stakes. Total network locations rose by 36 from a year ago to 293, and by 6 from last quarter. However, the yearly increase includes 24 US clinics operated by OrangeTwist, in which the company bought a minority stake late last year.
By our math, stripping out the 24 OrangeTwist clinics acquired at close leaves 12 locations added over the past year, or 4.7% underlying network growth. That pace is far below the 14% annual growth needed to reach 1,000 clinics by 2035. In addition, the company's share of losses from equity-method investments like OrangeTwist reached $0.59 million this quarter and $1.16 million over nine months.
What to watch: total network locations at year-end. Reaching 306 clinics by December is required to stay on the 14% annual growth path.
Currency Swings and Taxes Cut Into Net Profit
While operating profit rose 66.3% from a year ago, net income attributable to SBC Medical grew 22.4% to $15.7 million, and the net profit margin fell 3 percentage points to 26.8%. Because the company earns nearly all its revenue in Japanese yen but reports in US dollars, currency swings hit the bottom line directly.
The company recorded a $0.95 million foreign exchange loss this quarter, reversing a $0.92 million foreign exchange gain a year ago. Income tax expense also rose 65.3% to $9.38 million, and non-controlling interests — profit belonging to outside partners in subsidiaries like Waqoo — took $0.72 million, up from $0.01 million a year ago.
What to watch: the yen translation impact in the quarterly filing's management discussion, which will show how much currency moves held back dollar revenue.
Risks This Quarter Didn't Answer
Five standing concerns received no new data in the earnings release because the company has not yet filed its full quarterly report or held its conference call.
- Core vs Waqoo split: the release omits segment tables; the quarterly filing's segment note will show how much SBC Core grew on its own.
- Loyalty-point and procurement policy gains: the release omits revenue by service type; the filing's revenue note will show whether policy-driven revenue held up.
- Inbound medical tourism: promised two quarters ago, but the release gives no visitor count or revenue figure; the call and presentation are the next check.
- Financial outlook: the company again gave no numeric revenue or profit targets for the fourth quarter or full year.
- Founder share sales: no update on whether the chief executive plans further stock sales after his April offering.
👓 Other Themes
Biological Age Testing Starts the Longevity Push
SBC Medical plans to open longevity clinics in 2027 focused on preventive health. As a first step, Aikawa said the company is building "an in-house DNA methylation-based test to estimate biological age" using Waqoo's lab technology. It is also "developing a proprietary local large language model (LLM) infrastructure" — an internal AI system to handle patient records safely — while upgrading clinic software with partner Atomic Software.
💲 Other KPIs
Total advances from customers and related parties — cash collected upfront for treatment packages and loyalty points not yet used — fell 10.1% from last quarter and 44.0% from a year ago by our math. The balance has shrunk for four straight quarters following last year's loyalty-point rules change.
Uncollected bills owed by related-party partner clinics rose 12.4% by our math from $27.51 million at the end of December 2025. These balances typically build up during the year as SBC Medical bills the clinics and get paid down in the fourth quarter, absorbing $3.50 million of operating cash over the first nine months.
Weighted average shares outstanding were unchanged from last quarter and down 0.1% from a year ago by our math. The US-listed healthcare group has not bought back any stock this year, keeping 1.30 million shares in treasury at a cost of $7.75 million.
🔮 Guidance
Unchanged. SBC Medical gives no quarterly or full-year revenue targets, but confirmed that the August service fee revisions took effect in the third quarter. Management previously stated these revisions will add $15 million in annual revenue ($11 million+ from call centers and $4 million+ from clinic support), or about $3.75 million per quarter by our math.
❓ Key Questions
How much did SBC Core grow without Waqoo?
The press release combines SBC Core and the acquired Waqoo business into a single 35% revenue growth figure. Investors need the standalone SBC Core revenue and management services numbers to verify how much the August fee hike added.
Can partner clinics afford the $15M fee increase?
Related-party revenue jumped by $9.8 million from last quarter while clinic patient visits grew 9% and spend per visit rose 4%. Because the partner clinics pay SBC Medical's fees out of their own earnings, their profit margins determine whether the higher fees can last.
Why has spend per visit growth slowed to 4%?
Average spend per visit grew 11% from a year ago in the first quarter, 7% in the second quarter, and 4% ($290) in the third quarter. Management should clarify whether price competition in Japanese cosmetic clinics has returned.
When will management report inbound medical tourism numbers?
In the first quarter, management promised to share concrete customer numbers for international visitors, but the third-quarter release still omits them. Without visitor counts or revenue, investors cannot judge the overseas expansion strategy.